The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Open Targets Platform: supporting systematic drug–target identification and prioritisation
Open accessAbstract
The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target–disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-wide CRISPR knockout screens in 300 cancer models (Project Score), and GWAS/UK BioBank statistical genetic analysis evidence from the Open Targets Genetics Portal. We have evolved our evidence scoring framework to improve target identification. To aid the prioritisation of targets and inform on the potential impact of modulating a given target, we have added evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety. We have also developed the user interface and backend technologies to improve performance and usability. In this article, we describe the latest enhancements to the Platform, to address the fundamental challenge that developing effective and safe drugs is difficult and expensive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UniProt: a worldwide hub of protein knowledge
The UniProt Consortium (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1049 · Cited by 7,698
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1120 · Cited by 4,000 · cited 1×
“The Open Targets Genetics Portal addresses this problem by interpreting manually curated associations from the GWAS catalog, as well as independent signals from GWAS with publicly available summary statistics, most importantly the UK Biobank GWAS data (7,24,25).”
Self-citationInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
The DisGeNET knowledge platform for disease genomics: 2019 update
Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., & Furlong, L. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1021 · Cited by 2,639
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
ChEMBL: towards direct deposition of bioassay data
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1075 · Cited by 2,372
Self-citationThe reactome pathway knowledgebase 2022
Gillespie, M., Jassal, B., Stephan, R., Milacic, M., Rothfels, K., Senff-Ribeiro, A., Griss, J., Sevilla, C., Matthews, L., Gong, C., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1028 · Cited by 2,339
Toxicity Testing in the 21st Century: A Vision and a Strategy
Krewski, D., Acosta, D., Andersen, M., Anderson, H., Bailar, J. C., Boekelheide, K., Brent, R., Charnley, G., Cheung, V. G., Green, S., et al. (2010) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2010.483176 · Cited by 1,688
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0060-1 · Cited by 1,597
Self-citationZhou, W., Nielsen, J. B., Fritsche, L. G., Dey, R., Gabrielsen, M. E., Wolford, B. N., LeFaive, J., VandeHaar, P., Gagliano, S. A., Gifford, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0184-y · Cited by 1,544
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
King, E. A., Davis, J. W., & Degner, J. F. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008489 · Cited by 649
Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E. M., Hercules, A., Fumis, L., Miranda, A., Carvalho-Silva, D., Buniello, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa840 · Cited by 615
Self-citationModeling sample variables with an Experimental Factor Ontology
Malone, J., Holloway, E., Adamusiak, T., Kapushesky, M., Zheng, J., Kolesnikov, N., Zhukova, A., Brazma, A., & Parkinson, H. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq099 · Cited by 568
PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels
Martin, A. R., Williams, E., Foulger, R. E., Leigh, S., Daugherty, L. C., Niblock, O., Leong, I. U. S., Smith, K. R., Gerasimenko, O., Haraldsdottir, E., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0528-2 · Cited by 559
Self-citationOpen Targets: a platform for therapeutic target identification and validation
Koscielny, G., An, P., Carvalho-Silva, D., Cham, J. A., Fumis, L., Gasparyan, R., Hasan, S., Karamanis, N., Maguire, M., Papa, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1055 · Cited by 504
Self-citationOpen Targets Platform: new developments and updates two years on
Carvalho-Silva, D., Pierleoni, A., Pignatelli, M., Ong, C., Fumis, L., Karamanis, N., Carmona, M., Faulconbridge, A., Hercules, A., McAuley, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1133 · Cited by 472
Self-citationMungall, C. J., McMurry, J. A., Köhler, S., Balhoff, J. P., Borromeo, C., Brush, M., Carbon, S., Conlin, T., Dunn, N., Engelstad, M., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1128 · Cited by 441
Force, T., & Kolaja, K. L. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3252 · Cited by 363
Pharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279 · cited 1×
“Several other resources including Pharos (35), Disgenet (36) or CanSAR (37) given their respective areas of expertise (38).”
Shefchek, K. A., Harris, N. L., Gargano, M., Matentzoglu, N., Unni, D., Brush, M., Keith, D., Conlin, T., Vasilevsky, N., Zhang, X. A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz997 · Cited by 236
Expression Atlas update: from tissues to single cells
Papatheodorou, I., Moreno, P., Manning, J., Fuentes, A. M.-P., George, N., Fexova, S., Fonseca, N. A., Füllgrabe, A., Green, M., Huang, N., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz947 · Cited by 224
A genetics-led approach defines the drug target landscape of 30 immune-related traits
The ULTRA-DD Consortium, Fang, H., De Wolf, H., Knezevic, B., Burnham, K. L., Osgood, J., Sanniti, A., Lledó Lara, A., Kasela, S., De Cesco, S., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0456-1 · Cited by 220
Europe PMC: a full-text literature database for the life sciences and platform for innovation
The Europe PMC Consortium (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1061 · Cited by 158
canSAR: update to the cancer translational research and drug discovery knowledgebase
Coker, E. A., Mitsopoulos, C., Tym, J. E., Komianou, A., Kannas, C. C., Micco, P. D., Villasclaras-Fernández, E. D., Özer, B., Antolín, A. A., Workman, P., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1129 · Cited by 124
Donated chemical probes for open science
Müller, S., Ackloo, S. Z., Arrowsmith, C. H., Bauser, M., Baryza, J. L., Blagg, J., Böttcher, J., Bountra, C., Brown, P. J., Bunnage, M. E., et al. (2018) · eLife · doi:10.7554/elife.34311 · Cited by 104
Potential functional and pathological side effects related to off-target pharmacological activity
Lynch, J. J., Vleet, T. R. V., Mittelstadt, S. W., & Blomme, E. A. G. (2017) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2017.02.020 · Cited by 102
Approaches to target tractability assessment – a practical perspective
Brown, K. K., Hann, M. M., Lakdawala, A. S., Santos, R., Thomas, P. J., & Todd, K. (2018) · MedChemComm · doi:10.1039/c7md00633k · Cited by 69
Benchmarking network propagation methods for disease gene identification
Picart‐Armada, S., Barrett, S. J., Willé, D. R., Perera-Lluna, A., Gutteridge, A., & Dessailly, B. H. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007276 · Cited by 66
The eTOX Data-Sharing Project to Advance in Silico Drug-Induced Toxicity Prediction
Cases, M., Briggs, K. A., Steger‐Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., Schwab, C. H., Pastor, M., Wichard, J., & Sanz, F. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151121136 · Cited by 65
Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets
Maciejewski, M., Lounkine, E., Whitebread, S., Farmer, P. J., DuMouchel, W., Shoichet, B. K., & Urbán, L. (2017) · eLife · doi:10.7554/elife.25818 · Cited by 50
Deconvoluting Kinase Inhibitor Induced Cardiotoxicity
Lamore, S. D., Ahlberg, E., Boyer, S. K., Lamb, M. L., Hortigon-Vinagre, M. P., Rodriguez, V., Smith, G. L., Sagemark, J., Carlsson, L., Bates, S. M., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx082 · Cited by 42
Computational resources associating diseases with genotypes, phenotypes and exposures
Zhang, W., Zhang, H., Yang, H., Li, M., Xie, Z., & Li, W. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby071 · Cited by 28
Cited by
FinnGen provides genetic insights from a well-phenotyped isolated population
Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K. M., Reeve, M. P., Laivuori, H., Aavikko, M., Kaunisto, M. A., et al. (2023) · Nature · doi:10.1038/s41586-022-05473-8 · Cited by 4,233
Search and sequence analysis tools services from EMBL-EBI in 2022
Madeira, F., Pearce, M., Tivey, A. R. N., Basutkar, P., Lee, J., Edbali, O., Madhusoodanan, N., Kolesnikov, A., & Lopez, R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac240 · Cited by 2,267
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Zhao, J. H., Stacey, D., Eriksson, N., Macdonald-Dunlop, E., Hedman, Å. K., Kalnapenkis, A., Enroth, S., Cozzetto, D., Digby-Bell, J., Marten, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01588-w · Cited by 747
Mapping the proteo-genomic convergence of human diseases
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M. A., Oerton, E., Cook, J., Stewart, I. D., Kerrison, N. D., et al. (2021) · Science · doi:10.1126/science.abj1541 · Cited by 657
Metadata
- Authors
- Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M., Baker, J., Ferrer, J., Raies, A., Razuvayevskaya, O., Faulconbridge, A., Petsalaki, E., Mutowo, P., Machlitt-Northen, S., Peat, G., McAuley, E., Ong, C. K., Mountjoy, E., Ghoussaini, M., Pierleoni, A., Papa, E., Pignatelli, M., Koscielny, G., Karim, M., Schwartzentruber, J., Hulcoop, D. G., Dunham, I., & McDonagh, E. M.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-16
- Volume
- 49
- Issue
- D1
- Pages
- D1302-D1310
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W3106143834
- Cited by
- 495
- References
- 38
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.